Limitations of CT Angiography in Patient Selection for Thrombolytic Therapy To the Editor: We have read with great interest the article by Wildermuth et al1 on the role of CT angiography (CTA) in patient selection for thrombolytic therapy. The authors report that selection of patients with little potential for benefit from thrombolytic therapy is feasible with the use of CTA. The CTA findings, ...

BACKGROUND AND PURPOSE Widespread use of thrombolytic treatments, along with improved chances of survival after an initial ischemic stroke, increases the possibility of repeated thrombolysis. There are few reports, however, regarding repeated thrombolysis in patients who have suffered acute ischemic stroke. We explored the number and outcome of patients with repeated thrombolytic therapy in the...

This article is a summary of the Sol Sherry Lecture of the Council on Arteriosclerosis, Thrombosis, and Vascular Biology, which was presented at the 71st Scientific Sessions of the American Heart Association in November 1998.1 It highlights the work from our laboratory, designed to dissect the intricate reactions and molecular control mechanisms that operate in the final stages of the coagulati...

Background and Purpose—The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of acute and restorative stroke therapies. Summary of Review—At the STAIR VII recommendations for strategies to maximize the use of intravenous thrombolytics through targeting public education, and the refinement of current treatment exclusion criteria were propose...

Thrombolytic therapy, also known as clot busting drug, is a breakthrough treatment which has saved untold lives. It has been used in the clinical area to treat venous and arterial thromboembolic complaints which are a foremost cause of death. In 1761, Morgagni lead the way of thrombolytic therapy. Now day's different types of thrombolytic drugs are currently available in market: alteplase, anis...

BACKGROUND Post-myocardial infarction ventricular septal defect (VSD) complicates approximately 2% of myocardial infarctions. Thrombolytic therapy may accelerate the time from myocardial infarction to VSD formation. The effects of thrombolytic therapy in patients with a post-myocardial infarction VSD were investigated. METHOD Demographic, procedural, and event data were retrospectively analys...

Summary. Examination and treatment of 274 patients with acute deep vein thrombosis the lower limbs (DVT) was carried out. Thrombolytic therapy (TLT) as a basic method used in 98 (35.8 %) patients. Of these, 44 (16.1 underwent catheter-guided thrombolysis 54 (19.7 systemic thrombolytic therapy. Anticoagulant (ACT) 176 (64.2 In distant period, positive results TLT significantly exceeded ACT. Thus...

Background: Thrombolytic therapy in patients with sub-massive pulmonary embolism (SMPTE) needs further assessment. Objectives: The current study aimed to assess a potential benefit of thrombolytic and non-thrombolytic therapy in patients with SMPTE. Patients andMethods: One hundred-nineteen patients were enrolled with SMPTE from 2006 to 2010 in the tertiary care center of Rajaie medical and res...

BACKGROUND AND PURPOSE Thrombolytic therapy rate for acute ischemic stroke remains low, and improving public awareness of thrombolytic therapy may be helpful to reduce delay and increase chances of thrombolytic therapy. Our purpose was to survey the level of knowledge about thrombolytic therapy for acute ischemic stroke among community residents in Yuzhong district, Chongqing, China. METHODS ...

BACKGROUND AND PURPOSE There is little information about early outcome after intravenous application of tissue-type plasminogen activator (tPA) for stroke patients treated in community-based settings. We investigated the association between tPA therapy and in-hospital mortality in a pooled analysis of German stroke registers. METHODS Ischemic stroke patients admitted to hospitals cooperating ...